1. Home
  2. Labeler Index
  3. Northstar Rx Llc
  4. 16714-358
  5. Product Images: Levetiracetam

Product Images Levetiracetam

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 8 images provide visual information about the product associated with Levetiracetam NDC 16714-358 by Northstar Rx Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - levetiracetam fig1

Figure 1 - levetiracetam fig1

The text is a figure caption showing responder rates in Study 1, with percentages of 39.6% and 37.1% for two groups labeled as "Ll" and "Pcabo", respectively. There is also a note indicating that the Pcabo group was statistically significant compared to placebo.*

Figure 2 - levetiracetam fig2

Figure 2 - levetiracetam fig2

The text describes a figure called "Responder Rate" with results displayed as percentages for a study called "Study 2" in a period called "Period A". There are three percentages given as results, 35.2%, 208%, and 63%, and a comparison is made with a drug called Leveraceam and a placebo. The text appears to be part of a scientific or medical report.*

Figure 3 - levetiracetam fig3

Figure 3 - levetiracetam fig3

Figure 4 - levetiracetam fig4

Figure 4 - levetiracetam fig4

The text describes a figure showing the responder rate (>50% reduction from baseline) in Study 4. The figure shows percentage values ranging from 0% to 44.6% with a sample size of 97 patients who received the placebo. There is also a note stating that the result was statistically significant versus placebo.*

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

Figure 5: Responder Rate for All Patients Ages 1 Month to < 4 Years (≥ 50% Reduction from Baseline) in Study 5 - levetiracetam fig5

This is a figure showing the responder rate for patients aged 1 month to <4 years in Study 5. The responder rate is a 50% reduction from baseline. The placebo group (N=51) had a responder rate of 19.6%, while the levetiracetam group (N=58) had a responder rate of 43.5%, which is statistically significant versus placebo.*

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

Figure 6: Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7 - levetiracetam fig6

The text describes a figure (Figure 6) presenting the percentage of patients who responded (>50% reduction from baseline) to a treatment for PGTC seizure frequency per week in Study 7. The figure shows that 72.2% of patients who received Levetiracetam responded to the treatment compared to only 45.2% of patients who received placebo (N=84 and N=79 respectively). The text also specifies that the difference is statistically significant.*

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/mL (473 mL Bottle) - levetiracetam fig7

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 100 mg/mL (473 mL Bottle) - levetiracetam fig7

Chemical Structure - levetiracetam str

Chemical Structure - levetiracetam str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.